Meta‐analysis of randomized controlled trials comparing 17α‐hydroxyprogesterone caproate and vaginal progesterone for the prevention of recurrent spontaneous preterm delivery

Abstract

BackgroundVaginal progesterone and 17α‐hydroxyprogesterone (17α‐OHP) are both used to prevent preterm delivery in women who have experienced spontaneous preterm delivery (SPTD) previously. Randomized trial data of the comparative effectiveness of these interventions have been mixed.ObjectivesTo compare the efficacy of intramuscular 17α‐OHP and vaginal progesterone in the prevention of recurrent SPTD.Search strategyCochrane Central Register of Controlled Trials, African Journals Online, Embase, Google Scholar, ISI Web of Science, LILACS, CINAHL, PubMed, and registers of ongoing trials were searched using keywords related to 17α‐OHP, vaginal progesterone, and preterm delivery.Selection criteriaRandomized controlled trials published between January 1, 1966, and November 30, 2016, comparing 17α‐OHP and vaginal progesterone for the prevention of recurrent SPTD during singleton pregnancies were included.Data collection and analysisStudy data were extracted and meta‐analyses were performed when outcomes were comparable.Main resultsThe meta‐analyses included data from three randomized trials. Lower rates of SPTD before 34 weeks (relative risk 0.71, 95% confidence interval 0.53–0.95) and before 32 weeks (relative risk 0.62, 95% confidence interval 0.40–0.94) of pregnancy were observed among patients treated with vaginal progesterone.ConclusionsVaginal progesterone and 17α‐OHP were comparable for the prevention of recurrent SPTD in singleton pregnancies; vaginal progesterone could be superior.Vaginal progesterone was comparable to 17α‐hydroxyprogesterone for the prevention of recurrent spontaneous preterm delivery in patients with singleton pregnancies.